Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: Results of a worldwide expanded access program study

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1703-1709

  Samuels, B L ^a   Chawla, S ^b   Patel, S ^c   von Mehren, M ^d   Hamm, J ^e   Kaiser, P E ^f   Schuetze, S ^g   Li, J ^f   Aymes, A ^h   Demetri, G D ⁱ  

^a Kootenai Cancer Center   (United States)

^b Sarcoma Oncology Center   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e Norton Cancer Institute   (United States)

^f Oncology Specialists ^*  (United Kingdom)

^g UNIVERSITY OF MICHIGAN   (United States)

^h JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Expanded access program; L sarcoma; Objective response rate; Overall survival; Soft tissue sarcoma; Trabectedin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; DEXAMETHASONE; TRABECTEDIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; FATIGUE; FEMALE; HEALTH CARE ACCESS; HEALTH PROGRAM; HISTOPATHOLOGY; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84878445731     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds659     Document Type: Article

References (31)

1. Penel N, Nisse C, Feddal S et al. Epidemiology of soft tissue sarcomas in adults. Presse Med 2001; 30: 1405-1413.
2. Segal NH, Pavlidis P, Antonescu CR et al. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol 2003; 163: 691-700.
3. Walker JK. Nonrhabdomyosarcoma Soft Tissue Sarcomas. http://emedicine.medscape.com/article/991351-overview (24 May 2012, date last accessed).
4. National Cancer Institute. Childhood Soft Tissue Sarcoma Treatment (PDQ®). http://www.cancer.gov/cancertopics/pdq/treatment/child-soft-tissue-sarcoma/HealthProfessional/page1#Reference1.3 (7 June 2012, date last accessed).
5. Demetri GD, Antonia S, Benjamin RS et al. Soft tissue sarcoma. J Natl Compr Canc Netw 2010; 8: 630-674.
6. NCCN. Clinical Practice Guidelines in Oncology (NCCN Guidelines™): Soft tissue sarcoma. Version I.2011. http://www.nccn.org/index.asp (26 March 2012, date last accessed).
7. Lietman SA. Soft-tissue sarcomas: overview of management, with a focus on surgical treatment considerations. Cleve Clin J Med 2010; 77(Suppl 1): S13-S17.
8. Delaney TF, Kepka L, Goldberg SI et al. Radiation therapy for control of softtissue sarcomas resected with positive margins. Int J Radiat Oncol Biol Phys 2007; 67: 1460-1469.
9. Wesolowski R, Budd GT. Use of chemotherapy for patients with bone and softtissue sarcomas. Cleve Clin J Med 2010; 77(Suppl 1): S23-S26.
10. Milano A, Apice G, Ferrari E et al. New emerging drugs in soft tissue sarcoma. Crit Rev Oncol Hematol 2006; 59: 74-84.
11. Omura GA, Major FJ, Blessing JA et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983; 52: 626-632.
12. Muss HB, Bundy B, DiSaia PJ et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 1985; 55: 1648-1653.
13. Borden EC, Amato DA, Rosenbaum C et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987; 5: 840-850.
14. Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11: 1269-1275.
15. Antman K, Crowley J, Balcerzak SP et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11: 1276-1285.
16. Santoro A, Tursz T, Mouridsen H et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13: 1537-1545.
17. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003; 3: CD003293.
18. Jelic SK, Kovcin V, Milanovic N. Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. Eur J Cancer 1997; 33: 220-225.
19. Le Cesne A, Judson I, Crowther D et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000; 18: 2676-2684.
20. PharmaMar. PharmaMar Single Technology Appraisal Submission to The National Institute for Health and Clinical Excellence: Yondelis (trabectedin) for the treatment of soft tissue sarcoma. http://www.nice.org.uk/nicemedia/live/12049/44708/44708.pdf (17 November 2011, date last accessed).
21. Scotto KW. ET-743: more than an innovative mechanism of action. Anticancer Drugs 2002; 13(Suppl 1): S3-S6.
22. Yondelis. Summary of Product Characteristics; http://www.medicines.org.uk/EMC/medicine/20457/SPC/Yondelis+0.25+mg+powder+for+concentrate+for+solution+for+infusion+Yondelis+1+mg+powder+for+concentrate+for+solution+for+infusion/ (27 August 2011, date last accessed).
23. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
24. Garcia-Carbonero R, Supko JG, Manola J et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004; 22: 1480-1490.
25. Garcia-Carbonero R, Supko JG, Maki RG et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005; 23: 5484-5492.
26. Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005; 23: 576-584.
27. Yovine A, Riofrio M, Blay JY et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22: 890-899.
28. Christinat A, Leyvraz S. Role of trabectedin in the treatment of soft tissue sarcoma. OncoTargets Therapy 2009; 2: 105-113.
29. Demetri GD, Chawla SP, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27: 4188-4196.
30. Garcia-Del-Muro X, Lopez-Pousa A, Maurel J et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011; 29: 2528-2533.
31. Votrients®, (Pazopanib), Tablets: FDA Briefing Document Oncologic Drugs Advisory Committee Meeting (NDA 22-465); http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM298833.pdf (20 March 2012, date last accessed).